Selank
Neuropeptide
Also known as: TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP, tuftsin analog
Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No reliable primary plasma-PK figure. Vendor sources give mutually contradictory values (2-3 min, 2-10 min, and 20-30 min), none traceable to a primary source, so all are flagged unverified. Wikipedia's Selank entry reports NO PK parameters. Mechanistic primary work (PubMed 11550013, 12432865) shows Selank inhibits enkephalin-degrading enzymes in mouse plasma, which is a mechanism note, not a half-life.
No primary-sourced microgram dose obtained. Russian registered product is a 0.15% intranasal solution; circulating per-dose microgram figures are vendor/community-derived. Route is intranasal in registered use.
Registered in Russia with some clinical trial history, but Western peer-reviewed evidence is limited and much of it traces to the same Institute of Molecular Genetics (RAS) lineage as Semax. Limited independent replication and few blinded Western trials.
Lyophilised: General peptide convention: -20 C lyophilized (no compound-specific data).
Reconstituted: General convention: 2-8 C refrigerated (no compound-specific data).
Human safety data derives from Russian use; not Western-reviewed. Intranasal route in registered use. GABAergic/immunomodulatory activity reported.
- Selank, PubChem (molecular weight 751.9) · other
- The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity (PubMed 11550013) · pubmed
- Effects of Selank on behavioral reactions and plasma enkephalin-degrading enzyme activity in mice (PubMed 12432865) · pubmed